Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.

Slides:

Advertisements

Similar presentations

The concept of Diabetes & CV risk: A lifetime risk challenge Vascular function as an early sign of trouble: How can the inhibition of cholesterol absorption.

Advertisements

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.

Philip J. Barter, et al. Circulation 2011;124:

$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.

Pramlintide – An analog of amylin that overcomes the tendency of human amylin to: Aggregate, form insoluble particles Adhere to surfaces – Pharmacokinetic.

VBWG BRAVER Trial BRachial Artery Vascular Endothelium Reactivity Study A substudy of PROVE IT-TIMI 22.

Treatment month Adjusted mean change in IPSS from baseline (ITT, LOCF) Tamsulosin

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Copyright © 2003 American Medical Association. All rights reserved.

Infusion of Hi-Xen reduces the iAUCs for gastric emptying and postprandial glucose levels in humans with NGT, IGT, and T2DM. Infusion of Hi-Xen reduces.

Figure 1. Twenty-four-hour plasma ACTH concentrations in insomniacs (▪) and controls (○). The thick black line indicates the sleep recording period. The.

Westerweel PE et al. Eur Heart J 2008;29:

Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride.

Oxford Niacin Trial.

IL-1β stimulates CXCL5 and CXCL8 gene expression and protein secretion in A549 cells in a time- and dose-dependent manner. IL-1β stimulates CXCL5 and CXCL8.

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Bushinsky et al. Am J Nephrol 2016;44: (DOI: / )

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency Don P. Wilson, MD, FNLA, Mark Friedman,

Study Design Ketil Lunde, et al. N Engl J Med 2006;355:

Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al.

Effects of highly concentrated SFN provided as BSE in T2D patients

Patients with Kawasaki disease but not those with mimicking conditions have significantly elevated serum and urine levels of meprin A and filamin C, which.

Marina Cuchel, Dirk J. Blom, Maurizio R. Averna

Selected efficacy and safety parameters.

The impact of allergic rhinitis on bronchial asthma

FMD VP1-specific IgG, IgG1, and IgG2 in sera of guinea pigs (n = 6/group) immunized on days 1 and 21 by intramuscular injection of FMDV antigens (type.

Hajer GR et al. Atherosclerosis 2009;202:216-24

Sudhop T. et al. J Lipid Res 2009 Apr 20 [Epub ahead of print]

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.

Baseline Characteristics by Tertiles of Homocysteine

Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods Dmitri Sviridov et al.

Flow of Patients Through the Trial

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Study Participant Flow

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Disposition of Patients in the Atherogenic Dyslipidemia Study

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Eight serum analytes with greatest differences in levels between clinically infected and non-infected neonates. Eight serum analytes with greatest differences.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Baseline Characteristics by hs-CRP

The ACCORD Study Group. NEJM 2010; Epub March 14

Receiver operating characteristic curves (ROC) for the metabolites between the systemic inflammatory response syndrome (n=15) and sepsis (n=35) groups.

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Effects of embryonic hypoxia on fasted and postprandial cardiac output

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Skeletal muscle characteristics of HFD-induced obese mice.

Flow of study participants

BAFF-deficient (BAFFnull) and anti-BAFF antibody (Ab)–treated obese mice exhibit superior glucose metabolic control compared with WT and Bnull mice. BAFF-deficient.

Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or.

Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance. Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance.

Effects of Rosi treatment on ASKO mice.

Urinary albumin excretion and histology of glomeruli.

Average percent change in serum leptin and soluble leptin receptor (sOB-R) levels in response to rhLeptin administration at a low dose (0.01 mg/kg) (n.

GTTs and ITTs. A: GTTs of WT (◇), LepTg (♦), Akita (open circles), and LepTg:Akita (closed circles) mice at 8 and 16 weeks of age. GTTs and ITTs. A: GTTs.

Effect of empagliflozin on efficacy parameters at week 18.

Clinical characteristics and laboratory parameters in relation to dose of oral sodium bicarbonate. Clinical characteristics and laboratory parameters in.

Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome

Glycemic control and body weight over 52 weeks.

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Anti-Flk-1 mAb treatment reduces vessel density in tumors.

Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

Presentation transcript:

Yunoki K et al. Atherosclerosis 2011 Epub Apr 22

Baseline clinical characteristics Yunoki K et al. Atherosclerosis 2011 Epub Apr 22

Laboratory data and endothelial function during a fasting state before and after treatment for 4 weeks in the ezetimibe and control groups Yunoki K et al. Atherosclerosis 2011 Epub Apr 22

(A–C) Postprandial changes in serum TG, RLP-C and apoB-48 levels and the AUC for postprandial serum TG, RLP-C and apoB-48 levels before and after treatment for 4 weeks in the ezetimibe and control groups (D) Postprandial changes in %FMD and changes in maximum reduction of %FMD after the cookie test (max Δ%FMD) before and after treatment for 4 weeks in the ezetimibe and control groups Open bar indicates ezetimibe group; solid bar, control group Data are expressed as mean ± SE. *P < 0.05, vs. before treatment Yunoki K et al. Atherosclerosis 2011 Epub Apr 22

Postprandial changes in serum TG levels and the AUC for postprandial serum TG levels before and after treatment for 4 weeks in the ezetimibe and control groups (open bar indicates ezetimibe group; solid bar, control group) Data are expressed as mean ± SE. *P < 0.05, vs. before treatment

Yunoki K et al. Atherosclerosis 2011 Epub Apr 22 Postprandial changes in serum RLP-C levels and the AUC for postprandial serum RLP-C levels before and after treatment for 4 weeks in the ezetimibe and control groups (open bar indicates ezetimibe group; solid bar, control group) Data are expressed as mean ± SE. *P < 0.05, vs. before treatment

Yunoki K et al. Atherosclerosis 2011 Epub Apr 22 Postprandial changes in serum apoB-48 levels and the AUC for postprandial serum apoB-48 levels before and after treatment for 4 weeks in the ezetimibe and control groups (open bar indicates ezetimibe group; solid bar, control group) Data are expressed as mean ± SE. *P < 0.05, vs. before treatment

Yunoki K et al. Atherosclerosis 2011 Epub Apr 22 Postprandial changes in %FMD and changes in maximum reduction of %FMD after the cookie test (max Δ%FMD) before and after treatment for 4 weeks in the ezetimibe and control groups Data are expressed as mean ± SE. *P < 0.05, vs. before treatment